Inventor · disambiguated record
Vincent Jacques
Also filed as: JACQUES VINCENT
30 granted patents·27 pending applications·289 citations·filing 1998–2025
96Inventor score
Top patents by PatentIndex Score
57 records- 0198US9732031B2Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2014·Granted Aug 15, 2017·121 cites·9 claims
- 0295US9809603B1Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using sameDEUTERX LLC·Filed 2016·Granted Nov 7, 2017·12 cites·22 claims
- 0394US8957066B2Histone deacetylase inhibitorsREPLIGEN CORP·Filed 2013·Granted Feb 17, 2015·20 cites·13 claims
- 0493US9512143B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2015·Granted Dec 6, 2016·11 cites·18 claims
- 0589US9908899B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2016·Granted Mar 6, 2018·5 cites·24 claims
- 0688US11123336B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2019·Granted Sep 21, 2021·2 cites·21 claims
- 0786US10189858B2Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using sameDEUTERX LLC·Filed 2017·Granted Jan 29, 2019·3 cites·20 claims
- 0886US9540395B2Histone deacetylase inhibitorsJACQUES VINCENT·Filed 2012·Granted Jan 10, 2017·9 cites·26 claims
- 0985US12180137B1Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereofDEUTERX LLC·Filed 2024·Granted Dec 31, 2024·0 cites·15 claims
- 1083US10265305B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2017·Granted Apr 23, 2019·2 cites·9 claims
- 1183US10188639B2Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazoneDEUTERX LLC·Filed 2015·Granted Jan 29, 2019·3 cites·20 claims
- 1282US2024417368A1Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2024·Application pending·0 cites
- 1379US6056939ASelf-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticalsFiled 1998·Granted May 2, 2000·85 cites·33 claims
- 1478US11918569B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2021·Granted Mar 5, 2024·0 cites·28 claims
- 1578US2022213023A1Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2022·Application pending·0 cites
- 1676US8048906B2Optically pure and enriched isomers of chelating ligands and contrast agentsCATALYST MEDICAL·Filed 2006·Granted Nov 1, 2011·3 cites·33 claims
- 1776US2025268879A1Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2025·Application pending·0 cites
- 1875US10059723B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2016·Granted Aug 28, 2018·1 cites·26 claims
- 1974US2023218595A1Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disordersDEUTERX LLC·Filed 2022·Application pending·0 cites
- 2073US11141411B2Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2018·Granted Oct 12, 2021·0 cites·18 claims
- 2173US2021387940A1Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2021·Application pending·0 cites
- 2273US2022193055A1Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Application pending·0 cites
- 2372US8569259B2Adenosine analogs and their useBEN-ZEEV EFRAT·Filed 2007·Granted Oct 29, 2013·2 cites·21 claims
- 2472US2020148704A1Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2019·Application pending·0 cites
- 2571US10029988B2HDAC inhibitorsBIOMARIN PHARM INC·Filed 2014·Granted Jul 24, 2018·1 cites·28 claims
- 2669US10301323B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2018·Granted May 28, 2019·0 cites·14 claims
- 2767US10280182B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2018·Granted May 7, 2019·0 cites·10 claims
- 2867US8034898B2Methods of collagen imagingCOLLAGEN MEDICAL LLC·Filed 2006·Granted Oct 11, 2011·8 cites·17 claims
- 2967US2022362220A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2020·Application pending·0 cites
- 3066US2020253937A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2019·Application pending·0 cites
- 3165US10981933B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2019·Granted Apr 20, 2021·0 cites·16 claims
- 3264US11319313B2Crystalline forms of deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Granted May 3, 2022·0 cites·14 claims
- 3364US10526346B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2018·Granted Jan 7, 2020·0 cites·14 claims
- 3462US2023074827A1Crystalline forms of deuterium-enriched pioglitazonePOXEL SA·Filed 2022·Application pending·0 cites
- 3562US2025011277A1Modified forms of ambroxol for therapeutic useZYWIE LLC·Filed 2024·Application pending·0 cites
- 3661US8114894B2Bicyclic compounds and methods of making and using sameGHOSH SHOMIR·Filed 2009·Granted Feb 14, 2012·0 cites·4 claims
- 3761US2020239457A15-deutero-thiazolidinyldione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2019·Application pending·0 cites
- 3860US2017369420A1Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2017·Application pending·0 cites
- 3960US2018125827A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using sameDEUTERX LLC·Filed 2017·Application pending·0 cites
- 4060US2020390753A1Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disordersPOXEL SA·Filed 2019·Application pending·0 cites
- 4159US2019382351A1Hdac inhibitorsBIOMARIN PHARM INC·Filed 2019·Application pending·0 cites
- 4258US9255121B2Adenosine analogs and their useMICRODOSE THERAPEUTX INC·Filed 2013·Granted Feb 9, 2016·0 cites·16 claims
- 4357US10428028B2HDAC inhibitorsBIOMARIN PHARM INC·Filed 2018·Granted Oct 1, 2019·0 cites·20 claims
- 4456US2025235413A1Modified forms of ambroxol for therapeutic useZYWIE LLC·Filed 2022·Application pending·0 cites
- 4555US11767317B1Methods of synthesizing enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Granted Sep 26, 2023·0 cites·20 claims
- 4654US2018117026A1Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disordersDEUTERX LLC·Filed 2017·Application pending·0 cites
- 4754US2006155120A1Optically pure and enriched isomers of chelating ligands and contrast agentsAMEDIO JOHN C·Filed 2004·Application pending·0 cites
- 4852US9386938B2Methods for collagen imagingCARAVAN PETER D·Filed 2011·Granted Jul 12, 2016·1 cites·18 claims
- 4952US2018118730A15-deutero-thiazolidinyldione compounds and methods of treating medical disorders using sameDEUTERX LLC·Filed 2017·Application pending·0 cites
- 5048US2006275217A1Chemical exchange saturation transfer contrast agentsCARAVAN PETER D·Filed 2006·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Vincent Jacques files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →